Abstract 5699: Tegavivint directly targets TBL1 to inhibit b-catenin nuclear oncogenic activityAundrietta D. Duncan, Stephen Horrigan, Prashi Jain et al.|Cancer Research|2026Cited by 0
Abstract 3900: Tegavivint, a first-in-class TBL1 inhibitor demonstrates potent activity in WNT-driven colorectal cancers.Raffaella Soldi, Sunil Sharma, Jamie Cox et al.|Cancer Research|2026Cited by 0